A veterinarian or veterinary technician should demonstrate or instruct the pet owner regarding the appropriate technique for applying Selarid topically to dogs and cats prior to first use. Remove the applicator from the outer pouch using scissors or fold along diagonal line to expose nick; tear back at nick. Hold the applicator upright. Tap the narrow part of the applicator to ensure the contents remain within the main body of the applicator. Twist or snap back the tip. To administer the product, part the hair on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the applicator on the skin and squeeze the applicator 3 or 4 times to empty its entire contents directly onto the skin in one spot. Keeping the applicator squeezed, drag it away from the liquid and lift to remove. Check the applicator to ensure that it is empty. Do not massage the product into the skin. Due to alcohol content, do not apply to broken skin. Avoid contact between the product and fingers. Do not apply when the haircoat is wet. Bathing or shampooing the dog 2 or more hours after treatment will not reduce the effectiveness of Selarid against fleas or heartworm. Bathing or shampooing the cat 2 hours after treatment will not reduce the effectiveness of Selarid against fleas. Bathing or shampooing the cat 24 hours after treatment will not reduce the effectiveness of Selarid against heartworm. Stiff hair, clumping of hair, hair discoloration, or a slight powdery residue may be observed at the treatment site in some animals. These effects are temporary and do not affect the safety or effectiveness of the product. Discard empty applicators in your ordinary household refuse.
For the prevention and control of flea infestations, Selarid should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. In controlled laboratory studies >98% of fleas were killed within 36 hours. Results of clinical field studies using selamectin solution monthly demonstrated >90% control of flea infestations within 30 days of the first dose. Dogs and cats treated with selamectin solution, including those with pre-existing flea allergy dermatitis, showed improvement in clinical signs associated with fleas as a direct result of eliminating the fleas from the animals and their environment.
If the dog or cat is already infested with fleas when the first dose of Selarid is administered, adult fleas on the animal are killed and no viable fleas hatch from eggs after the first administration. However, an environmental infestation of fleas may persist for a short time after beginning treatment with Selarid because of the emergence of adult fleas from pupae.
For the prevention of heartworm disease, Selarid must be administered on a monthly basis. Selarid may be administered year-round or at least within one month after the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of Selarid and resumption of monthly dosing will minimize the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of Selarid must be given within a month of the last dose of the former medication.
Selamectin, the active ingredient in Selarid, is a macrocyclic lactone compound. These compounds effectively prevent the development of adult heartworms when administered to dogs and cats within one month of exposure to infective (L3 ) Dirofilaria immitis larvae. Efficacy of macrocyclic lactones decreases below 100% in dogs, however, if first administered >2 months after exposure to infective larvae. Thus, in heartworm endemic regions, delaying initiation of heartworm prevention using Selarid beyond 2 months of first exposure to infective larvae (e.g., starting puppies and kittens at >8 weeks of age), or gaps of >2 months in the administration of Selarid during periods of heartworm transmission, increases the risk of the animal acquiring heartworms. Animals with unknown heartworm history that test negative for heartworms prior to the initiation of Selarid may be harboring pre-patent infections at the time Selarid was started. Testing such animals 3–4 months after initiation of Selarid would be necessary to confirm their negative heartworm status. At the discretion of the veterinarian, cats ≥6 months of age may be tested to determine the presence of existing heartworm infections before beginning treatment with Selarid. Cats already infected with adult heartworms can be given Selarid monthly to prevent further infections.
For the treatment of ear mite (O. cynotis) infestations in dogs and cats, Selarid should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Selarid will control any subsequent ear mite infestations. In the clinical field trials ears were not cleaned, and many animals still had debris in their ears after the second dose. Cleansing of the infested ears is recommended to remove the debris.
For the treatment of sarcoptic mange (S. scabiei) in dogs, Selarid should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of Selarid will control any subsequent sarcoptic mange mite infestations. Because of the difficulty in finding sarcoptic mange mites on skin scrapings, effectiveness assessments also were based on resolution of clinical signs. Resolution of the pruritus associated with the mite infestations was observed in approximately 50% of the dogs 30 days after the first treatment and in approximately 90% of the dogs 30 days after the second monthly treatment.
For the control of tick (Dermacentor variabilis) infestations in dogs, Selarid should be administered on a monthly basis. In heavy tick infestations, complete efficacy may not be achieved after the first dose. In these cases, one additional dose may be administered two weeks after the previous dose, with monthly dosing continued thereafter.
For the treatment and control of intestinal hookworm (A. tubaeforme) and roundworm (T. cati) infections, Selarid should be applied once as a single topical dose.
Selamectin solution has been tested safe in over 100 different pure and mixed breeds of healthy dogs and over 15 different pure and mixed breeds of healthy cats, including pregnant and lactating females, breeding males and females, puppies six weeks of age and older, kittens eight weeks of age and older, and avermectin-sensitive collies. A kitten, estimated to be 5–6 weeks old (0.3 kg), died 8 ½ hours after receiving a single treatment of selamectin solution at the recommended dosage. The kitten displayed clinical signs which included muscle spasms, salivation and neurological signs. The kitten was a stray with an unknown history and was malnourished and underweight (see WARNINGS).
DOGS: In safety studies, selamectin solution was administered at 1, 3, 5, and 10 times the recommended dose to six-week-old puppies, and no adverse reactions were observed. The safety of selamectin solution administered orally also was tested in case of accidental oral ingestion. Oral administration of selamectin solution at the recommended topical dose in 5- to 8-month-old beagles did not cause any adverse reactions. In a pre-clinical study selamectin was dosed orally to ivermectin-sensitive collies. Oral administration of 2.5, 10, and 15 mg/kg in this dose escalating study did not cause any adverse reactions; however, eight hours after receiving 5 mg/kg orally, one avermectin-sensitive collie became ataxic for several hours, but did not show any other adverse reactions after receiving subsequent doses of 10 and 15 mg/kg orally. In a topical safety study conducted with avermectin-sensitive collies at 1, 3 and 5 times the recommended dose of selamectin solution, salivation was observed in all treatment groups, including the vehicle control. Selamectin solution also was administered at 3 times the recommended dose to heartworm infected dogs, and no adverse effects were observed.
CATS: In safety studies, selamectin solution was applied at 1, 3, 5, and 10 times the recommended dose to six-week-old kittens. No adverse reactions were observed. The safety of selamectin solution administered orally also was tested in case of accidental oral ingestion. Oral administration of the recommended topical dose of selamectin solution to cats caused salivation and intermittent vomiting. Selamectin solution also was applied at 4 times the recommended dose to patent heartworm infected cats, and no adverse reactions were observed.
In well-controlled clinical studies, selamectin solution was used safely in animals receiving other frequently used veterinary products such as vaccines, anthelmintics, antiparasitics, antibiotics, steroids, collars, shampoos and dips.
VetLabel.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VetLabel.com. Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.